Company Overview of Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The company’s lead product candidate, ADS-5102 is in Phase 3 clinical development for the treatment of a movement disorder, known as levodopa-induced dyskinesia associated with Parkinson’s disease. ADS-5102 is also in a Phase 2 clinical study for the treatment of symptoms associated with various sclerosis, including walking impairment. The company’s portfolio also includes Namzaric (memantine HCl extended release and donepezil HCl) capsules; and Namenda XR (memantine HCI) extended release capsules. It ha...
1900 Powell Street
Emeryville, CA 94608
Founded in 2000
Key Executives for Adamas Pharmaceuticals, Inc.
Chairman and Chief Executive Officer
Total Annual Compensation: $748.8K
Chief Operating Officer
Total Annual Compensation: $436.1K
Senior Vice President of Product Development
Total Annual Compensation: $503.0K
Compensation as of Fiscal Year 2014.
Adamas Pharmaceuticals, Inc. Key Developments
Adamas Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
Nov 12 15
Adamas Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported a net loss attributable to common stockholders of $14.9 million, or $0.81 per basic and diluted share. In the same period last year, the company reported a net loss attributable to common stockholders of $9.6 million, or $0.57 per basic and diluted share. The company reported total revenue of $0.8 million compared with $0.22 million a year ago. Loss from operations was $14.99 million compared with $9.6 million a year ago. Loss before income taxes was $14.9 million compared with $9.6 million a year ago.
For the nine months, the company reported a net loss attributable to common stockholders of $41.1 million, or $2.28 per basic and diluted share. For the nine months ended September 30, 2014, the company recorded net income attributable to common stockholders of $53,000, or $0.00 per basic and diluted share. The company reported total revenues of $1.4 million compared with $25.5 million a year ago. Loss from operations was $41.4 million compared with income from operations of $1.5 million a year ago. Loss before income taxes was $41.1 million compared with income of $0.68 million a year ago. Net cash used in operating activities was $34.9 million compared with net cash provided by operating activities of $7.2 million a year ago. Purchases of property and equipment were $1.1 million compared with $0.19 million a year ago.
Adamas Pharmaceuticals, Inc. Presents Nonclinical Findings Supporting the Potential Use of ADS-5102 for the Treatment of Multiple Sclerosis Gait
Oct 12 15
Adamas Pharmaceuticals, Inc. announced findings from two nonclinical studies that demonstrate the potential of ADS-5102 for the treatment of multiple sclerosis (MS) symptoms. One study demonstrated improvement in walking in vivo models of MS. Data from the second study provide insights into the potential mechanisms of action of amantadine in MS. These results (Abstract P863) were presented at the 31stCongress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Barcelona, Spain. Researchers conducted nonclinical studies designed to evaluate the efficacy of amantadine for the treatment of MS-related symptoms, including walking impairment, in vivo models of MS and to better understand the mechanisms of action of amantadine in MS. Data demonstrated that in models of MS, chronic administration of amantadine at a dose intended to match the human plasma levels of ADS-5102 improved walking. Additionally, data from an in vitro study demonstrated that amantadine blocked neuronal potassium channel activity, which may result in enhanced electrical impulses across demyelinated regions of neurons. Data from these studies suggest that ADS-5102 may have clinical utility in the treatment of major symptoms associated with MS, including walking impairment. About MS: MS is a chronic autoimmune-mediated disorder that affects approximately 270,000 people in the United States. While there are multiple drugs approved to reduce inflammation and slow the development of symptoms early in the disease course, there are limited options available for the treatment of the frequent and often persistent neurological symptoms. In a 2013 patient survey on MS in America, 76% of respondents reported walking difficulties and 89% reported fatigue. About ADS-5102: the company's wholly-owned product candidate is ADS-5102 (amantadine HCl), an extended-release version of amantadine that is intended for once daily administration at bedtime. ADS-5102 is designed to improve upon the pharmacokinetic (PK) profile of immediate release amantadine, with the aim of enhancing efficacy without compromising the known tolerability profile. In PK studies, ADS-5102 has been shown to achieve high plasma amantadine concentrations in the early morning that are sustained throughout the afternoon and are lower in the evening, potentially providing therapeutic benefit when needed most. Adamas is currently evaluating ADS-5102 in Phase 3 clinical trials for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and in a Phase 2 clinical trial for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. There are currently no approved drugs in the United States or Europe for the treatment of LID.
Adamas Pharmaceuticals, Inc. Presents at BIO-Europe 2015, Nov-02-2015
Oct 1 15
Adamas Pharmaceuticals, Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|